Why the study?
Acute exacerbations of COPD are frequent and linked to poor prognosis; the study aimed to evaluate whether the PRADO-BPCO home discharge care bundle reduces 28-day readmissions after hospitalization for AECOPD.
Does the PRADO-BPCO home discharge care bundle reduce the 28-day readmission or death rate in patients hospitalized for AECOPD?
Does the PRADO-BPCO home discharge care bundle reduce the 28-day readmission or death rate in patients hospitalized for AECOPD?
The PRADO-BPCO home discharge care bundle did not reduce 28-day readmission or death rates compared to standard care in patients hospitalized for AECOPD, though the intervention group had more severe baseline disease.
Does not support PRADO-BPCO adoption to lower 28-day events; leaves open efficacy in randomized trials of severe AECOPD.
Purpose: Acute exacerbations of COPD (AECOPD) are frequent and associated with a poor prognosis. A home discharge care bundle, the PRADO-BPCO program, has been set up by the French National Health System in order to reduce readmission rate after hospitalization for AECOPD. This program includes early consultations by the general practitioner, a nurse, and a physiotherapist after discharge. The aim of our study was to evaluate the effect of the PRADO-BPCO program on the 28-days readmission rate of COPD patients after hospitalization for AECOPD. Patients and methods: This was a retrospective cohort study including all patients admitted for AECOPD in our center between November 2015 and January 2017. The readmission or death rate at 28 days after hospitalization for AECOPD was compared between patients included in the PRADO-BPCO program and patients with standard care after discharge. Inclusion in the program was decided by the physician in charge of the patient. Results: A total of 62 patients were included in the PRADO-BPCO group and 202 in the control group. At baseline, patients in the PRADO group had a more severe COPD disease and more severe exacerbations than the control group and mean inpatient stay was shorter in the PRADO group: 8.6±4.3 vs 10.4±7.4 days ( P =0.034). Readmission or death rate at 28 days was similar between groups: 10 (16.1%) in the PRADO group vs 30 (14.9%) in the control group ( P =0.81). Ninety-days readmission or death rate and overall survival were similar in the two groups. Conclusion: In our center, despite more severe COPD and a shorter hospitalization time, the PRADO-BPCO program failed to prove a benefit on the 28 days readmission or death rate when compared with standard care.
No takes yet. Share an insight, caveat, or question.
Cousse et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: